Retatrutide
An investigational single-peptide agonist designed to activate the GIP, GLP-1 and glucagon receptor pathways.
Receptor Targets
GIP, GLP-1 and glucagon receptor activity.
Week Phase 3 Trial
The main TRIUMPH-1 treatment period.
Week Endpoint
The extended study observation endpoint.
Highest Studied Dose
The highest reported TRIUMPH-1 trial dose.